Apheresis Nurse Jobs
Join Circulate Health as an apheresis nurse performing TPE at longevity clinics across the US. Flexible locations and meaningful work.

Circulate Health gives clinics the ability to deliver therapeutic plasma exchange to patients.
circulate.healthCrawled Oct 31, 2026
Join Circulate Health as an apheresis nurse performing TPE at longevity clinics across the US. Flexible locations and meaningful work.
Circulate Health offers guidance on Therapeutic Plasma Exchange (TPE) for longevity, toxin reduction, or medical indications.
Therapeutic plasma exchange (TPE) removes microplastics, toxins, and inflammatory proteins clinically shown to reduce biological age 2.6 years.
Circulate Health provides clinics with a turnkey program to offer Therapeutic Plasma Exchange (TPE), including FDA-cleared devices and trained nurses.
Circulate's Aging Cell trial showed TPE reduced biological age by 2.6 years. Explore the clinical evidence behind plasma exchange for longevity.
Dr. Brad Youngren discusses Therapeutic Plasma Exchange (TPE) as a regenerative medicine breakthrough with Elizabeth Tringali, PA-C.
Circulate Health presents clinical findings showing measurable reductions in circulating microplastics after Therapeutic Plasma Exchange (TPE).
A landmark clinical trial shows TPE reduced biological age by 2.6 years.
The page examines debates over evidence in the growing longevity medicine market.
Dr. Brad Younggren, CEO of Circulate Health, explains how therapeutic plasma exchange reduces biological age and removes microplastics.
Circulate's TPE clinical trial earned a New York Times feature, spotlighting its potential to reduce biological age through plasma exchange.
Khosla Ventures backs Circulate Health's TPE at longevity clinics — a treatment shown to reduce biological age and remove inflammatory toxins.
Latest clinical research, TPE updates, and longevity news from Circulate Health — covering plasma exchange, microplastics, and biological aging.
Circulate Health pioneers FDA-cleared TPE to reduce biological age, remove microplastics, and extend healthspan — backed by clinical research.
Circulate Health delivers Therapeutic Plasma Exchange (TPE) through a clinical model built for safety, consistency, and patient experience. For patients, that means care that’s guided by expert apheresis nurses. For clinics, it means a reliable partner in delivering TPE with confidence.
FDA-cleared Therapeutic Plasma Exchange (TPE) clinically shown to reduce biological age by 2.6 years. Remove microplastics and toxins.
Viome acquires Circulate Health to combine plasma exchange technology with its precision nutrition platform. The move integrates Circulate’s blood filtration methods into Viome’s microbiome and metabolomic analysis tools. This acquisition targets personalized health interventions for aging populations and metabolic disorders.
Viome acquires Circulate Health to integrate its therapeutic plasma exchange (TPE) technology. The move expands Viome’s capabilities in precision health interventions. Circulate Health specializes in treating autoimmune and chronic diseases via plasma filtration.
Viome acquires Circulate Health, a Seattle-based startup specializing in plasma exchange technology for longevity research. The move consolidates expertise in blood-based biomarkers and age-related interventions under Viome’s microbiome-focused platform. Circulate Health’s proprietary methods aim to extend healthy lifespans through targeted plasma treatments.
Circulate Health partners exclusively with Reborne to introduce its advanced therapeutic plasma exchange (TPE) protocols in the UK for the first time. Reborne becomes the country’s first hospital to offer these procedures, marking Circulate Health’s inaugural European collaboration. The agreement expands access to the biotechnology company’s specialized treatments in a new regional market.
Bryan Johnson and Gwyneth Paltrow are exploring plasma exchange as a potential method to reduce microplastics in the blood. Early research examines whether the procedure can remove these particles from circulation. The treatment involves filtering blood to separate plasma, which may contain microplastics, from other components.
Circulate Health secures $12 million in funding to expand its blood-cleaning service aimed at extending human lifespan. The company targets longevity through proprietary filtration technology designed to remove toxins from the bloodstream. Early adopters reportedly pay premium pricing for the procedure, positioning Circulate Health at the intersection of biotech and anti-aging markets.